Back to Report Store Home

Global Cardiovascular Disease Drugs Market to 2023 – Expiries, Acquisitions and New Products for Deep Vein Thrombosis, Pulmonary Arterial Hypertension and Dyslipidemia to Shake-Up the Competitive Landscape

  • Published: Dec-2017
  • Report Code: GBIHC461MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Cardiovascular Disease Drugs Market, Global, Epidemiology Patterns for Hypertension, 2016–2023 24

Figure 2: Cardiovascular Disease Drugs Market, Global, Epidemiology Patterns for Dyslipidemia, 2016–2023 25

Figure 3: Cardiovascular Disease Drugs Market, Global, Epidemiology Patterns for Heart Failure, 2016–2023 26

Figure 4: Cardiovascular Disease Drugs Market, Global, Key Marketed Products and Approved Indications, 2017 37

Figure 5: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Lipitor ($bn), 2006–2023 39

Figure 6: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Crestor ($bn), 2006–2023 40

Figure 7: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Zetia ($bn), 2006–2023 41

Figure 8: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Praluent ($bn), 2015–2023 43

Figure 9: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Repatha ($bn), 2016–2023 44

Figure 10: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Plavix ($bn), 2006–2023 45

Figure 11: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Xarelto ($bn), 2011–2023 47

Figure 12: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Eliquis ($bn), 2012–2023 48

Figure 13: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Brilinta ($bn), 2011–2023 49

Figure 14: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Entresto ($bn), 2015–2023 51

Figure 15: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Benicar ($bn), 2006–2023 52

Figure 16: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Bevyxxa ($m), 2017–2023 53

Figure 17: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Uptravi ($bn), 2016–2023 54

Figure 18: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Opsumit ($bn), 2013–2023 56

Figure 19: Cardiovascular Disease Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017 59

Figure 20: Cardiovascular Disease Drugs Market, Global, Pipeline by Stage of Development and Molecule Type, 2017 60

Figure 21: Cardiovascular Disease Drugs Market, Global, Pipeline for Key Cardiovascular Disease Indications by Stage of Development, 2017 62

Figure 22: Cardiovascular Disease Drugs Market, Global, Pipeline for Key Cardiovascular Disease Indications by Molecule Type, 2017 63

Figure 23: Cardiovascular Disease Drugs Market, Global, Pipeline by Molecular Target and Stage of Development, 2017 65

Figure 24: Cardiovascular Disease Drugs Market, Global, Pipeline by Molecular Target Breakdown, 2017 66

Figure 25: Cardiovascular Drugs Market, Global, Pipeline for Key Cardiovascular Disease Indications by Molecular Target, 2017 67

Figure 26: Cardiovascular Disease Drugs Market, Global, Clinical Program Attrition Rates by Stage of Development (%), 2006–2017 68

Figure 27: Cardiovascular Disease Drugs Market, Global, Clinical Trial Failure Rates (Phases I–III) and Overall Clinical Trial Attrition Rates by Indication (%), 2006–2017 69

Figure 28: Cardiovascular Disease Drugs Market, Global, Clinical Trial Failure Rates (Phases I–III) and Overall Clinical Trial Attrition Rates by Molecule Type (%), 2006–2017 70

Figure 29: Cardiovascular Disease Drugs Market, Global, Clinical Trial Failure Rates (Phases I–III) and Overall Clinical Trial Attrition Rates by Molecular Target (%), 2006–2017 71

Figure 30: Cardiovascular Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2017 72

Figure 31: Cardiovascular Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2017 73

Figure 32: Cardiovascular Disease Drugs, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2017 74

Figure 33: Cardiovascular Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2017 75

Figure 34: Cardiovascular Disease Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2017 76

Figure 35: Cardiovascular Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2017 77

Figure 36: Cardiovascular Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2017 78

Figure 37: Cardiovascular Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2017 79

Figure 38: Cardiovascular Disease Drugs Market, Global, Aggregate Clinical Program Size by Stage of Development (participants), 2006–2017 80

Figure 39: Cardiovascular Disease Drugs Market, Global, Aggregate Clinical Program Size by Stage of Development and Indication (participants), 2006–2017 81

Figure 40: Cardiovascular Disease Drugs Market, Global, Aggregate Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2017 82

Figure 41: Cardiovascular Disease Drugs Market, Global, Aggregate Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2017 83

Figure 42: Cardiovascular Disease Drugs Market, Global, Revenue Forecast for Inclisiran ($bn), 2020–2023 85

Figure 43: Cardiovascular Disease Drugs Market, Global, Revenue Forecast for MEDI-6012 ($m), 2020–2023 86

Figure 44: Cardiovascular Disease Drugs Market, Global, Revenue Forecast for Volanesorsen ($m), 2018–2023 89

Figure 45: Cardiovascular Disease Drugs Market, Global, Revenue Forecast for Vericiguat ($m), 2019–2023 91

Figure 46: Cardiovascular Disease Drugs Market, Global, Revenue Forecast for Bempedoic acid ($m), 2019–2023 93

Figure 47: Cardiovascular Disease Drugs Market, Global, Market Size ($bn), 2016–2023 95

Figure 48: Cardiovascular Disease Drugs Market, Global, Key Products Market Share, 2016–2023 99

Figure 49: Cardiovascular Drugs Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2016–2023 100

Figure 50: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Drugs Targeting Elements of the Coagulation Cascade ($bn), 2016–2023 103

Figure 51: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Drugs Acting on RAS ($bn), 2016–2023 104

Figure 52: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for P2Y12 Inhibitors ($bn), 2016–2023 105

Figure 53: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for HMG-CoA Inhibitors ($bn), 2016–2023 106

Figure 54: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for PCSK9 Inhibitors ($bn), 2016–2023 107

Figure 55: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Beta Blockers ($bn), 2016–2023 108

Figure 56: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Drugs Acting on Prostaglandin Receptors ($bn), 2016–2023 109

Figure 57: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Drugs Acting on Endothelin Receptors ($bn), 2016–2023 110

Figure 58: Cardiovascular Disease Drugs Market, Global, Cluster by Growth and Market Share, 2016–2023 111

Figure 59: Cardiovascular Disease Drugs Market, Global, Company Analysis Matrix, 2017 112

Figure 60: Cardiovascular Disease Drugs Market, Global, Forecast Market Share by Company (%), 2016–2023 115

Figure 61: Cardiovascular Diseasse Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2016–2023 116

Figure 62: Cardiovascular Disease Drugs Market, Global, Sanofi Annual Revenue Forecast, 2016–2023 117

Figure 63: Cardiovascular Disease Drugs Market, Global, AstraZeneca Annual Revenue Forecast, 2016–2023 118

Figure 64: Cardiovascular Disease Drugs Market, Global, Novartis Annual Revenue Forecast, 2016–2023 119

Figure 65: Cardiovascular Disease Drugs Market, Global, Bayer Annual Revenue Forecast, 2016–2023 120

Figure 66: Cardiovascular Disease Drugs Market, Global, Pfizer Annual Revenue Forecast, 2016–2023 121

Figure 67: Cardiovascular Disease Drugs Market, Global, Johnson and Johnson, Annual Revenue Forecast, 2016–2023 122

Figure 68: Cardiovascular Disease Drugs Market, Global, Bristol-Myers Squibb, Annual Revenue Forecast, 2016–2023 123

Figure 69: Cardiovascular Disease Drugs Market, Global, Merck & Co, Annual Revenue Forecast, 2016–2023 124

Figure 70: Cardiovascular Disease Drugs Market, Global, High-Activity and Late-Stage Pipeline Developers by Type, 2017 125

Figure 71: Cardiovascular Disease Drugs Market, Global, Pipeline, Overall, High-Activity and Late-Stage Developers by Level of Cardiovascular Specialization, 2017 126

Figure 72: Cardiovascular Disease Drugs Market, Global, Proportion of Total Company Revenue Attributed to Cardiovascular Disease, 2016–2023 127

Figure 73: Cardiovascular Disease Drugs, Global, Licensing Deals by Region, Value and Year, 2006–2017 129

Figure 74: Cardiovascular Disease Drugs Market, Global, Licensing Deals by Indication, 2006–2017 130

Figure 75: Cardiovascular Disease Drugs, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006–2017 131

Figure 76: Cardiovascular Disease Drugs Market, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target, 2006–2017 132

Figure 77: Cardiovascular Disease Drugs Market, Global, Licensing Deals with Disclosed Deal Values, 2006–2017 133

Figure 78: Cardiovascular Disease Drugs, Global, Co-development Deals by Region, Value and Year, 2006–2017 135

Figure 79: Cardiovascular Drugs Market, Global, Co-development Deals by Indication, 2006–2017 136

Figure 80: Cardiovascular Disease Drugs Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2017 137

Figure 81: Cardiovascular Disease Drugs Market, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target, 2006–2017 138

Figure 82: Cardiovascular Disease Drugs Market, Global, Co-development Deals with Disclosed Deal Values, 2006–2017 139

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards